Introduction
MHC class II molecules bind and display antigenic peptides as class II-peptide complexes on the cell surface of antigen-presenting cells (APCs) 1 for recognition by CD4 ϩ T helper cells (1) (2) (3) . The molecular mechanisms leading to formation of class II-peptide complexes and presentation of antigen on the cell surface begin with synthesis of class II ␣␤ heterodimers in the endoplasmic reticulum. Early during biosynthesis these ␣␤ heterodimers associate with a type II membrane protein, the invariant chain (Ii), to form a nonameric complex of ␣␤ Ii (4, 5) . Ii associates with class II molecules via direct interaction of residues 81-104 of its lumenal domain (6, 7) , designated CLIP (class II-associated Ii peptide), with the antigen binding groove of class II (8) (9) (10) . This ␣␤ Ii complex traverses the Golgi apparatus and is delivered to intracellular compartments (11) (12) (13) . In these acidic compartments, the Ii is degraded and liberated from the ␣␤ Ii complexes, allowing class II molecules to encounter and bind antigenic peptides. Most class II alleles require an additional class II-like molecule, HLA-DM (murine H-2M), to liberate the peptide-binding groove of CLIP, and to facilitate loading with antigenic peptide (14) (15) (16) .
Proteolysis participates in generation of class II-peptide complexes at two critical junctures. First, proteolytic degradation of the Ii is a prerequisite for peptide binding to class II molecules, as intact ␣␤ Ii trimers themselves are unable to bind peptides (17) . Inhibition of Ii degradation in B lymphoblastoid cells and murine spleen cells leads to accumulation of class IIassociated Ii fragments and inhibition of class II-peptide formation (18) (19) (20) (21) . Second, proteolysis of large polypeptides is required to generate the antigen presented by class II molecules (3) . These peptide antigens are 15-25 amino acids long, and are generated in the endosomal pathway from both exogenous and endogenous sources (8) . Selective inhibition of the proteases responsible for both these degradative processes is a potential mechanism for modulating the immune response.
Several lysosomal proteases have been implicated in the processing of Ii and antigenic peptides. Cathepsin B, the most abundant cysteine protease, has been tied to Ii degradation using purified class II-Ii complexes (22) . Cathepsin L, a potent cysteine-class endoprotease, binds to and is specifically inhibited by a fragment of the alternatively spliced Ii form p41 (23) . Overexpression of p41 in class II-and Ii-transfected mouse fibroblasts results in inhibition of cathepsin L activity and accumulation of Ii degradation products (24) . Interestingly, this leads to enhanced presentation of some antigenic peptides, suggesting that cathepsin L may be involved in Ii processing as well as peptide degradation in these cells. Cathepsin D, a prominent aspartyl protease, is able to generate antigenic peptides capable of associating with class II molecules (25, 26) .
We have shown recently that another cysteine protease, cathepsin S, plays a key role in processing Ii in human B lymphocytes (27) . Cathepsin S possesses potent endoproteolytic activity, is highly expressed in APCs, has a broad pH activity profile, and is upregulated by IFN-␥ . Specific inhibition of cathepsin S in human B lymphoblasts causes accumulation of a 13-kD Ii breakdown intermediate, interfering with subsequent class II-peptide association. Purified human cathepsin S, but not cathepsins B or D, is able to completely degrade Ii from class II-Ii complexes, generating class II-CLIP. In mouse splenocytes, inhibition of cathepsin S also induces buildup of Ii breakdown products and attenuation of class II-peptide association, although the extent of this effect appears to be haplotype dependent (28). Studies presented here expand upon the biochemical alterations in Ii processing and class II-peptide binding to examine the functional effects of cathepsin S inhibition in murine B lymphocytes and in vivo immunity. First we show that specific inhibition of cathepsin S with the vinyl-sulfone inhibitor LHVS (29) in a mouse B cell line blocks presentation of an immunodominant ovalbumin (OVA) peptide (30) by interfering with class II-peptide association, not by inhibiting generation of this antigenic peptide. Next, we document that in vivo administration of LHVS selectively inhibits cathepsin S and interferes with Ii processing and antigen presentation in murine spleen cells. This, in turn, leads to a diminished immune response to OVA as characterized by antibody titers and lung eosinophilia in a murine model of pulmonary hypersensitivity. These findings suggest that cathepsin S plays an important role in processing of class II-Ii in mouse B cells to generate class II molecules competent for binding antigenic peptide, and that inhibition of cathepsin S is possible in vivo and has important functional consequences in modulating the immune response.
Methods
Materials. Cbz-Tyr-Ala-CN 2 was a generous gift from Dr. Elliot Shaw (Friedrich Miescher-Institut, Basel, Switzerland). LHVS (morpholinurea-leucine-homophenylalanine-vinylsulfone phenyl), an irreversible, specific cathepsin S inhibitor was prepared as described previously (Arris Pharmaceuticals, South San Francisco, CA) (29) . Stock solutions of LHVS were made in DMSO. OVA was purchased from Sigma Chemical Co. (St. Louis, MO) and was phosphorylcholine (PC)-haptenated as described previously (31) .
[ I were obtained from DuPont New England Nuclear (Boston, MA). Protein A-agarose was purchased from Boehringer Mannheim (Indianapolis, IN). Methionine-, cysteine-free DME, penicillin/streptomycin (100 ϫ ), Hepes (100 ϫ ), nonessential amino acids (100 ϫ ), sodium pyruvate (100 ϫ ), and glutamine (100 ϫ ) were obtained from GIBCO BRL (Gaithersburg, MD). RPMI was purchased from Fisher Scientific (Pittsburgh, PA) and FBS was obtained from Hyclone Labs (Logan, UT). Normal rabbit serum, normal mouse serum, 2-mercaptoethanol, Ficoll, Histopaque, o -phenylenediamine dihydrochloride, Percoll, Tween 20, avidin-peroxidase, and BSA were purchased from Sigma. Maxisorb Nunc immunoplates were purchased from Marsh, Inc. (Rochester, NY). The trinitrophenol (TNP)-Ficoll and TNP-BSA were purchased from Solid Phase Sciences (San Rafael, CA).
Antibodies. N22 is a hamster mAb that recognizes mouse MHC class II molecules (32) , and was a gift of Dr. R.M. Steinman (The Rockefeller University, New York). The anti-mouse IgE antibody, anti-mouse kappa light chain conjugated to biotin, and anti-mouse IgM conjugated to horseradish peroxidase (HRP) were purchased from PharMingen (San Diego, CA). The secondary HRP antibody used in the OVA-specific IgG ϩ IgM titers was purchased from Kirkegaard & Perry (Gaithersburg, MD). Antiserum against mouse cathepsin L was a gift of Dr. M.M. Gottesman (National Institutes of Health, Bethesda, MD) and anti-human cathepsin B, which crossreacts with mouse cathepsin B, was purchased from Athens Research (Athens, GA). Antiserum against mouse cathepsin S was raised using methods as described previously (33) .
Animals. Female C57BL/6 mice (6-8 wk old) were purchased from Harlan Sprague Dawley (Indianapolis, IN) and The Jackson Laboratories (Bar Harbor, ME). Animals were housed in a viral-free barrier facility.
Cell culture. The mouse B cell hybridoma line A20 ( ␥ 2a ϩ , ϩ , H-2 d ), transfected with PC-specific human heavy chain (31) was maintained in RPMI with 10% FBS, 1:1,000 U/ml penicillin, 100 mg/ ml streptomycin, and 2 mM glutamine. The T cell hybridoma cell line DO.11.10 recognizes OVA peptide 323-339 (OVA 323-339 ) in context of I-A d and I-A b (30, 34) and was maintained in RPMI supplemented with FBS, glutamine, penicillin/streptomycin as above in addition to 50 M 2-mercaptoethanol, 10 M nonessential amino acids, and 100 M sodium pyruvate. The IL-2-dependent cell line HT-2 was maintained in the same medium supplemented with 100 U/ml IL-2. The I-A dexpressing M12.4.1 cell line and its class II Ϫ variant M12.C.3 (35) were generous gifts of Dr. Laurie Glimcher (Harvard School of Public Health, Boston, MA), and were maintained in the same medium.
Active site labeling of cysteine proteases. The cysteine protease inhibitor Cbz-Tyr-Ala-CN 2 was iodinated as reported previously (36) . A20 cells (4 million/sample) in RPMI were incubated with LHVS or DMSO vehicle at 37 Њ C for 1 h before labeling. Cells were then labeled by incubation with Cbz-[ 125 I]-Tyr-Ala-CN 2 for 1 h at 37 Њ C, washed twice with PBS, and lysed in SDS-PAGE sample buffer. Mouse spleen cells (10 million/sample) were labeled as above without prior incubation with inhibitors.
Metabolic labeling and class II immunoprecipitation. Mouse spleen cells (20 million/sample) were preincubated in 1 ml methionine-, cysteine-free DME for 1 h at 37 Њ C before labeling with 0.55 mCi [ 35 S]methionine/cysteine for 1 h at 37 Њ C. The cells were centrifuged and resuspended in RPMI/10% FBS and chased for 4 h. Then, the cells were washed twice with cold PBS and lysed in 1 ml of 50 mM TrisHCl, pH 7.4, 0.5% NP-40, 5 mM MgCl 2 . Lysates were precleared with protein A-agarose, 7 l of normal rabbit serum, and 2 l of normal mouse serum followed by immunoprecipitation with mAb N22 coupled to protein A-agarose. Immunoprecipitates were washed four to six times with 1 ml of 50 mM Tris-HCl, pH 7.4, 0.5% NP-40, 5 mM EDTA, 150 mM NaCl. These pellets were eluted directly with nonreducing or reducing SDS-PAGE sample buffer and analyzed by 12% SDS-PAGE.
Subcellular fractionation. A20 cells were fractionated as previously described (37) . Briefly, cells were suspended in 6 ml homogenization buffer (0.3 M sucrose, 0.01 M Hepes, 10 g/ml leupeptin, 40 g/ml pepstatin A, and 200 M PMSF, pH 7.2) and ruptured by nitrogen cavitation after an equilibrium at 450 psi for 5 min at 4 Њ C. Postnuclear supernatants were centrifuged over 24 ml of 25.4% Percoll with 0.3 M sucrose, 0.01 M Hepes, and the same protease inhibitors as above (pH 7.2, ␦ ϭ 1.129 g/ml) for 65 min at 30,000 g . Fractions of 0.8 ml were recovered from each gradient by gravity siphon.
The distribution of plasma membrane was defined by enzymatic activity of alkaline phosphodiesterase I, and the distribution of lysosomes was determined by activity of ␤ -hexosaminidase as previously described (37) . The distributions of human mIgM and murine class II molecules were detected by ELISA as previously described (37) .
Antigen presentation assays. A20 cells were incubated with 2 nM LHVS or vehicle for 1 h at 37 Њ C. Cells were aliquoted into wells of a 96-well plate at 2 ϫ 10 5 cells/well in the presence of inhibitor and 0-100 g/ml final concentration PC-OVA and incubated for 24 h with 10 5 cells/well of the T cell hybridoma DO.11. Each sample was assayed in triplicate. Generation of IL-2 was assayed by proliferation of IL-2-dependent cell line HT-2 measured by incorporation of [ 3 H]thymidine (38) . An IL-2 standard curve was prepared for each experiment. For some control experiments, A20 cells were incubated with LHVS for 1 h at 37 Њ C and then fixed in 1% paraformaldehyde/PBS for 30 min at room temperature. The cells were washed four times and then incubated (10 5 cells/well) with 2 nM LHVS, 0-50 g/ml OVA 323-339 (purchased from Analytical Biotechnology Services, Boston, MA), and DO.11 T cells for 24 h at 37 Њ C.
The distribution of antigenic activity in the Percoll gradients capable of stimulating DO.11 cells was assayed as described previously (37) . Briefly, aliquots of each fraction were sonicated (model 250; Branson Ultrasonics Corp., Danbury, CT) with a microtip at power level 1.5, and incubated for 4 h at 37 Њ C with 5 ϫ 10 5 paraformaldehyde-fixed class II-positive M12.4.1 or class II-negative M12.C.3 APCs. After washing with culture medium, 10 5 APCs were incubated with 10 5 DO.11 cells in triplicate in a final volume of 0.2 ml. Proliferation of the IL-2 responsive reporter cell HT-2 was assessed after 24 h as described above. In this assay A20 cell fractions after incubation with PC-F(ab Ј )2-RGG are unable to stimulate DO.11 T cells (37 Animal immunization protocols. Mice were injected intraperitoneally with 100 mg/kg LHVS in DMSO every 48 h starting 2 d before immunization and continuing throughout the protocols. Control animals were injected with DMSO alone.
For the first immunization protocol, mice were immunized intraperitoneally on day 0 with 100 g OVA in 100 l of CFA. 7 d later the animals were boosted with a 200-l intraperitoneal injection containing 10 g of OVA and 1 mg of Al(OH) 3 . Animals were killed on day 14 with 5 mg sodium pentobarbital given intraperitoneally. Postimmune serum was obtained by cardiac puncture and spleen cells were harvested for cysteine protease labeling and evaluation of class II-Ii processing. As a control experiment mice were challenged with a T cell-independent antigen, TNP-Ficoll, and TNP-specific IgM was measured after 7 d as described previously (39) . Briefly, mice were injected with 100 g of TNP-conjugated Ficoll intraperitoneally in PBS. Animals were killed after 7 d and serum was collected by cardiac puncture. Preimmune sera in all experiments were obtained retroorbitally after animals were anesthetized with inhalation of 2-5% halothane.
Allergic pulmonary inflammation was induced as described previously (40, 41) . Briefly, animals were immunized on day 0 with 0.5 ml containing 8 g OVA and 1 mg Al(OH) 3 gel. The OVA was allowed to conjugate to the Al(OH) 3 gel for 1 h at room temperature before immunization. On day 5 the mice were boosted in an identical manner to the initial immunization. On day 12 the mice were exposed to nebulized 0.5% OVA in PBS for 1 h in the morning and 1 h in the afternoon. Animals were killed on day 15 as above.
ELISA for antibody titers. Total serum IgE was assayed by sandwich ELISA. Maxisorb Nunc immunoplates were coated with 2 g/ml rat anti-mouse IgE mAb clone R35-72 in 0.1 M NaHCO 3 , pH 8.2, at 4 Њ C overnight. Plates were washed three times with PBS/0.05% Tween and blocked for 2 h with PBS/3% BSA at room temperature. Plates were washed three times and incubated with serum samples diluted in PBS/1% BSA (1:20-1:500) and incubated overnight at 4 Њ C. Plates were washed four times and incubated with 2 g/ml rat antimouse kappa light chain antibody conjugated to biotin in PBS/1% BSA for 1 h at room temperature. Plates were washed five times and incubated with avidin-peroxidase (1:5,000) for 1 h at room temperature. Plates were washed six times, developed with o -phenylenediamine dihydrochloride, and the absorption measured at 450 nm. Results were quantitated against a standard curve generated with a purified mouse IgE standard (PharMingen) and the increase in IgE between pre-and postimmune serum was calculated for each mouse. Data were then expressed as a stimulation index comprised of the ratio of increased IgE for each immunized mouse divided by the mean increase in IgE for mice injected with adjuvant only.
To measure OVA-specific IgG ϩ IgM, Nunc immunoplates were coated with 20 g/ml OVA in 0.1 M NaHCO 3 , pH 8.2, at 4 Њ C overnight. Plates were washed and incubated with diluted serum samples as above. Plates were then incubated with goat anti-mouse IgG ϩ IgM antibody conjugated to HRP and developed as above. TNP-specific IgM was measured by coating Nunc immunoplates with 20 g/ml TNP-BSA as above, incubated with diluted serum samples (1:1,000), and then probed with anti-mouse IgM conjugated to HRP. For each mouse, postimmune serum dilutions in which OD was proportional to dilution were determined and then the change in OD between preand postimmune sera was determined at the same dilution. Data were expressed as the change in OD for each mouse. In some experiments (see Fig. 6 ), the mean change in OD for the group of nonimmunized controls was subtracted from that of the immunized mice.
Bronchoalveolar lavage (BAL). BAL was performed as described previously (42) . Briefly, trachea were surgically exposed and a small incision was made proximal to the carina. A 19-gauge tubing adapter was introduced into the trachea, secured with sutures, and the lungs were lavaged twice with 1 ml of PBS/0.6 mM EDTA. Total cells were counted and cytospin preparations were prepared for Wright-Giemsa staining. Eosinophils were identified by the usual histologic criteria.
After lavage, lungs were reinflated with 10% phosphate-buffered formalin and placed in a container with the same fixative. Lungs were then embedded in paraffin and sectioned. Lung sections were stained with hematoxylin and eosin and examined microscopically for evidence of inflammation.
Eotaxin-and KC-induced inflammatory responses. Peritoneal eosinophilia was induced by intraperitoneal administration of eosinophil-chemoattractant eotaxin. Mice were injected with 2 nM LHVS or DMSO as above for 14 d (three mice in each group). The day after the last injection they were treated with 2 g eotaxin intraperitoneally. Mouse recombinant eotaxin was a gift of Dr. Giu-Quin Jia (Millennium Pharmaceuticals, Cambridge, MA). After 2 h the mice were killed as above and lavage was performed by instillation and removal of 10 cm 3 RPMI from the peritoneal cavity. Total eosinophil counts were performed by analysis of the lavage fluid as described above.
Pulmonary inflammation and neutrophilia were induced by nasal insufflation of neutrophil chemokine KC (43) . Recombinant mouse KC was a gift of Dr. David Waltz (Children's Hospital, Boston, MA). After a 14-d treatment with LHVS or vehicle, mice were anesthetized with 5% halothane, and 1.5 g KC in 50 l PBS nasally instilled. 4 h after nasal insufflation of KC, mice were killed and BAL was performed as above. Neutrophils were identified after Giemsa staining by the usual histologic criteria.
Results
Cathepsin S and antigen presentation and processing in A20 cells. Cathepsin S is essential for efficient processing of Ii from class II-Ii complexes, to permit subsequent class II-peptide association in human B cells and murine splenocytes (27, 28) . Will this biochemical alteration in Ii processing lead to a functional deficit in antigen presentation? Moreover, will inhibition of cathepsin S block generation of the antigenic peptide? To address these important issues, antigen processing and presentation after specific inhibition of cathepsin S were examined in the A20 murine B cells.
The cysteine protease profile of A20 cells was determined by incubation with the cysteine-class protease inhibitor Cbz-[
125 I]-Tyr-Ala-CN 2 ( Fig. 1 A) . As previously described (27), Cbz-[ Fig. 1 A, first lane) . The identities of these bands were confirmed by immunoprecipitation with specific antisera (data not shown). Prior incubation of A20 cells with low concentrations of LHVS produced a slightly different labeling pattern ( Fig.   1 A, second through fourth lanes). LHVS at 1 and 2 nM inhibited cathepsin S alone, whereas LHVS at 5 nM began to attenuate the activity of cathepsin L. Thus, low concentrations of LHVS (1-2 nM) can be used to specifically inhibit cathepsin S activity in A20 cells.
To determine if specific inhibition of cathepsin S activity can functionally alter antigen presentation, A20 cells transfected with surface immunoglobulin against PC were incubated with PC-OVA in the absence and presence of 2 nM LHVS. Antigen presentation was assessed by stimulation of OVA-specific T cell clone DO.11.10. This hybridoma can react to OVA or OVA peptide (residues 323-339) presented by class II molecules of either H-2 d or H-2 b haplotype (34) . Inhibition of cathepsin S had a profound effect on the ability of A20 cells to present OVA (Fig. 1 B) . To examine whether LHVS alters T cell proliferation independently of antigen presentation, fixed A20 cells were incubated with OVA 323-339 peptide and DO.11 cells in the presence (ϩLHVS) and absence (ϪLHVS) of 2 nM LHVS (Fig. 1 C) . Antigen presentation in this model occurs via surface displacement of class II-bound peptides by OVA 323-339 , and is independent of Ii and antigen processing. LHVS had no effect on the ability of T cells to respond to OVA 323-339 peptide presented by fixed A20 cells. Thus, specific inhibition of cathepsin S in mouse B cells markedly attenuates antigen presentation of an immunodominant OVA peptide.
We next determined if inhibition of cathepsin S blocks generation of the antigenic epitope, or rather blocks the ability of the antigenic peptides to associate with class II molecules. The latter paradigm is most consistent with the biochemical alterations observed in human B lymphoblasts after inhibition of cathepsin S (27) . A20 cells were incubated with PC-OVA for 15-30 min in the absence (Fig. 2, left) or presence (Fig. 2, right) of 2 nM LHVS, lysed, and centrifuged over a Percoll gradient to separate intracellular compartments based on their intrinsic densities. Incubation of A20 cells with LHVS in this assay did not alter antigen uptake as evidenced by the distribution of human chain, nor did it alter the distribution of class II molecules, plasma membrane marker, or lysosomal marker (Fig. 2,  A and B (M12.C.3). Consistent with previous studies (37), uninhibited A20 cells were able to generate peptide in lysosomal compartments (fractions 2-5) and endosomes (fractions 7-11) (Fig.  2 C) . Class II-peptide complexes were primarily generated in the nonlysosomal, endosomal compartments. After specific inhibition of cathepsin S with LHVS, A20 cells were able to generate antigenic OVA fragments in these compartments (Fig.  2 C) . However, these same fractions were completely devoid of class II-peptide complexes, implying that the generated peptide is unable to associate with class II molecules. Thus, cathepsin S is necessary to render class II molecules competent for binding peptide, but does not qualitatively alter generation of OVA peptide with the capacity to stimulate DO.11 cells in the presence of class II molecules. This is consistent with its role as the protease primarily responsible for Ii processing in both human and murine APCs.
Inhibition of cathepsin S in vivo. Since inhibition of cathepsin S can block Ii processing (27, 28 ) and antigen presentation There was no LHVS present in the medium during this pulse-chase experiment. Cells were lysed and class II molecules were immunoprecipitated with mAb N22. Pellets from each sample were divided in half and analyzed under mildly denaturing (nonreducing) conditions, both boiled (b) and nonboiled (nb), on 12% SDS-PAGE. (C) Antigen presentation of OVA by mouse spleen cells after in vivo treatment with LHVS. C57BL/6 mice were injected every 48 h for 14 d with either 100 mg/kg LHVS or vehicle. The day after the last injection, spleen cells were harvested and incubated at 2 ϫ 10 5 cells/well with OVA and 10 5 cells/ well T cell hybridoma DO.11. IL-2 production was assayed in the supernatant after 24 h. There was no LHVS present in the medium during the assay. All samples were run in triplicate. Each data point represents the meanϮSEM of splenocytes from four animals. (Figs. 1 and 2 ) in professional APCs, selective targeting of cathepsin S activity in vivo is a tantalizing prospect for altering the immune response. Can cathepsin S activity be selectively blocked pharmacologically in vivo, and how will this alter the immune response? To study these questions C57BL/6 mice were injected intraperitoneally with the selective cathepsin S inhibitor LHVS. Cysteine protease activity after LHVS administration in splenocytes was assessed by incubation with Cbz-[ 125 I]-Tyr-Ala-CN 2 . Time course experiments demonstrated that cathepsin S remained fully inhibited for up to 48 h after a single injection of LHVS at 100 mg/kg, whereas at 72 h, recovery of activity was demonstrable (data not shown). Thus, selective inhibition of cathepsin S can be achieved by intraperitoneal administration of 100 mg/kg LHVS every 48 h. Fig. 3 A shows the cysteine protease activity pattern of murine splenocytes after intraperitoneal injection of LHVS at 100 mg/kg every 48 h for 14 d, 48 h after the final injection. Murine spleen cells primarily express two cysteine proteases labeled by the active site inhibitor Cbz-[ 125 I]-Tyr-Ala-CN 2 : cathepsin B running at 32 kD (single chain form) and 6 kD (light chain form), and cathepsin S running at 28 kD ( Fig. 3 A, first lane) . The identities of these bands were confirmed by immunoprecipitation with specific antisera (data not shown). Cathepsin S, but not cathepsin B, activity was inhibited in spleen cells from mice injected with 100 mg/kg LHVS at 48 h after injection (Fig. 3 A, second lane) . This same pattern of cysteine protease activity was observed in alveolar macrophages obtained by BAL (data not shown).
In vivo administration of LHVS results in a marked alteration of Ii processing and class II-peptide complex formation (Fig. 3 B) . Spleen cells from mice injected with 100 mg/kg LHVS (or vehicle) every 48 h for 14 d were harvested, pulselabeled for 1 h, and chased for 4 h. LHVS was not included during this pulse-chase experiment. The cells were then lysed and the class II molecules were immunoprecipitated with hamster mAb N22, which reacts against both Ii-associated and Iifree class II complexes (28, 32). Samples were analyzed by SDS-PAGE, with or without previous boiling, to evaluate the formation of SDS-stable class II-peptide complexes. Cells from mice injected with vehicle alone demonstrated the normal pattern of class II maturation (Fig. 3 B, first and second lanes), with polypeptide bands corresponding to class II ␣ and ␤ chains, and a higher molecular weight band in the nonboiled sample representing SDS-stable class II-peptide complexes (21) . Intact Ii was observed migrating very close to the ␤ chain.
In contrast, spleen cells from mice injected with LHVS revealed a marked accumulation of class II-associated lip10 Ii fragment and a concomitant blockage of SDS-stable class IIpeptide complex generation (Fig. 3 B, third and fourth lanes) . The appearance of a larger molecular weight complex in the third lane of Fig. 3 represents accumulation of ␣␤-lip10 Ii, which only partially dissociates under these conditions (28). Thus, inhibition of cathepsin S by administration of LHVS in vivo inhibits complete degradation of Ii and subsequent formation of SDS-stable ␣␤-peptide complexes.
To determine if this biochemical Ii processing defect translates into a functional presentation deficit, spleen cells from LHVS-treated (or vehicle-treated) animals were used to process and present OVA to the T cell hybridoma DO.11. LHVS was absent during this presentation assay. Spleen cells from mice treated with LHVS demonstrated a clear functional deficit in antigen presentation (Fig. 3 C) . Interestingly, inhibition of cathepsin S by administration of LHVS did not result in decreased expression of total class II (as determined by flow cytometry) or peptide-bound class II molecules (as analyzed by biotinylation and immunoprecipitation of surface MHC class II molecules) (data not shown). These data, together with the pulse-chase experiment (Fig. 3 B) , suggest that inhibition of cathepsin S delays, but does not completely block, formation of class II-peptide complexes.
To examine whether administration of LHVS for 2 wk in vivo results in gross T cell dysfunction, spleen cells from mice treated with LHVS (or vehicle) were used as responding cells in PHA stimulation assays and in a mixed lymphocyte reaction with irradiated Balb/c spleen cells as stimulators. [ 3 H]Thymidine uptake after stimulation by heterologous spleen cells or PHA was similar for both groups (Fig. 4) .
Inhibition of cathepsin S and immunity. What are the functional consequences of cathepsin S inhibition on the immune response? We compared the capacity of LHVS-treated and vehicle-treated animals to elicit an immune response in two different models of OVA-induced immunity. The first model assessed the ability of LHVS-treated animals to mount a humoral immune response when challenged with OVA in the presence of CFA. The second model looked at the ability of LHVS-treated animals to elicit a pulmonary inflammatory and hypersensitivity response when sensitized by intraperitoneal administration of alum-precipitated OVA, and subsequently challenged with nebulized OVA.
In the first model, C57BL/6 mice were injected with LHVS, or vehicle alone, every 48 h for 2 wk starting on day Ϫ2 (Fig.  5 A) . An immune response was elicited by intraperitoneal injection of OVA in CFA at day 0 with boost administered at day 7. Pre-and postimmune sera were collected and OVAspecific IgGϩIgM antibody titers determined by ELISA. Inhibition of cathepsin S resulted in a reduction, but not total abrogation, of the humoral immune response (Fig. 5 B) . Only one animal treated with LHVS responded normally to OVA. The reason for this deviation is presently unclear, but could be related to uneven administration of the inhibitor, or cellular compensatory mechanisms during long-term inhibition of cathepsin S. To examine the functionality of B cells in LHVStreated mice independent of antigen processing and presentation, mice were injected with T cell-independent antigen TNPFicoll, and TNP-specific IgM production measured after 1 wk (Fig. 5 C) (39) . There was no difference in generation of TNP-specific IgM between the LHVS-treated and vehicle (DMSO)-treated animals. Thus, inhibition of cathepsin S by administration of LHVS significantly alters antigen presentation-dependent antibody production without affecting the ability of B cells to respond to a T cell-independent antigen.
To examine the immune response in an alternative animal model, pulmonary inflammation and hypersensitivity were induced in mice as described previously (Fig. 6 A) (40, 41) . Briefly, mice were sensitized by two intraperitoneal injections of OVA conjugated to aluminum hydroxide gel 5 d apart. On day 12 mice were exposed to nebulized OVA for 2 h. 3 d after nebulization, sera were obtained for IgE titers and BALs were performed for evidence of eosinophilia. This model has been characterized extensively and produces a brisk IgE response in the serum, and a perivascular eosinophilic infiltration in the lung, evidence of pulmonary hypersensitivity, and inflammation (40, 41) . LHVS (or vehicle) was administered beginning 2 d before the initial immunization and every 48 h thereafter. Control mice (3-4/experiment) were not sensitized with intraperitoneal injection of OVA but were exposed to nebulized OVA.
Selective inhibition of cathepsin S mitigates both the generation of antibody titers and the hypersensitivity inflammatory reaction in the lung. LHVS attenuated the development of OVA-specific IgG ϩ IgM titers (Fig. 6 B) and total IgE titers (Fig. 6 C) . Further evidence of functionally important immune sequelae produced by inhibition of cathepsin S is shown by analysis of eosinophils in the BALs (Fig. 6 D) . The BALs from mice not sensitized with OVA had normal numbers of alveolar macrophages (350 ϫ 10 3 ), but no eosinophils. Sensitization and inhalation with OVA in control animals resulted in a marked influx of eosinophils in BAL fluid (Ͼ 50%) (Fig. 6 D) , with a small but significant increase in polymorphonuclear granulocytes and lymphocytes (data not shown). Treatment with LHVS profoundly blocked these inflammatory changes as reflected by the near absence of eosinophils in the BAL fluid (Fig. 6 D) . Histological sections of lungs from control mice show a prominent perivascular infiltration of inflammatory cells, which is blocked by treatment with LHVS (compare Fig.  7 B with C) .
To determine whether LHVS nonspecifically inhibits eosinophil migration or pulmonary inflammation, two antigen-inde- Preand postimmune sera were collected, diluted 1:100 with PBS/1% BSA, and OVAspecific IgG ϩ IgM measured by ELISA as described in Methods. Each treatment group consisted of six mice. Data analysis was performed by ANOVA with Tukey's multiple comparison test. (C) Separate C57BL/6 mice were immunized intraperitoneally with 100 g T cell-independent antigen TNP-Ficoll. Pre-and postimmune (7 d) sera were collected, diluted 1:500 with PBS/1% BSA, and TNP-specific IgM was measured as described in Methods. Each treatment group consisted of six mice. pendent models of cytokine-induced inflammatory reactions were used. In the first model, intraperitoneal administration of eotaxin induced peritoneal eosinophilia in both vehicle-and LHVS-treated animals. The mean (ϮSEM) peritoneal eosinophil count per animal was 2.55 (Ϯ0.46) ϫ 10 6 in vehicle-treated mice and 2.40 (Ϯ1.0) ϫ 10 6 in LHVS-treated mice (n ϭ 3 in both groups). There were no eosinophils in peritoneal lavages from control mice. KC is an ␣-chemokine able to induce a potent, neutrophilic pulmonary reaction by tracheal instillation in a rat model of pulmonary inflammation (43, 44) . Similarly, we are able to induce an exuberant, neutrophilic pulmonary inflammatory reaction in mice by nasal insufflation of 1.5 g of KC (our unpublished observations). LHVS did not abrogate this reaction when compared with vehicle-treated mice: there were 14.5 ϫ 10 6 neutrophils/animal in BAL fluid from LHVStreated animals, and 7.7 ϫ 10 6 neutrophils/animal in BAL fluid from DMSO-treated mice.
Discussion
This manuscript presents the first direct evidence that selective inhibition of cysteine proteases in vivo has important func- tional consequences for MHC class II-dependent immune responses. Several lines of evidence lead us to conclude that the mechanism underlying the immune modulating effects of cathepsin S inhibition is most likely secondary to alterations in class II-Ii processing and subsequent peptide loading. First, specific inhibition of cathepsin S in a B cell line (A20) leads to a profound inhibition in presentation of an OVA peptide ( Figs. 1 and 2 ). This antigen presentation defect results from an inability of antigenic peptide to associate with class II molecules, and is not a consequence of a defect in antigen processing. This is consistent with the previous finding that leupeptin, a nonspecific cysteine protease inhibitor, inhibits presentation of this OVA peptide in A20 cells (45) . Second, when administered in vivo, LHVS produces marked alterations in splenocyte MHC class II-Ii processing, peptide loading, and antigen presentation (Fig. 3) . This is consistent with alterations of class II-Ii processing produced by inhibition of cathepsin S in murine splenocytes ex vivo (28). Third, splenic T cells from mice treated with LHVS responded well when stimulated by PHA or in a mixed lymphocyte reaction, making gross T cell dysfunction an unlikely explanation for our data (Fig. 4) . Finally, LHVS did not appreciably alter the inflammatory reaction in three antigen-independent models of inflammation (T cellindependent antigen immunization; eotaxin-induced peritoneal eosinophilia; KC-induced pulmonary neutrophilia). Together, these data support the hypothesis that cathepsin S, previously shown to be important in Ii processing in vitro, regulates MHC class II function and subsequent immune responses in vivo. Although pulse-chase experiments revealed a marked defect in Ii processing and class II-peptide binding of freshly isolated splenocytes deficient in cathepsin S, in vivo inhibition of cathepsin S did not completely ablate the humoral response to OVA (Figs. 5 and 6 ). This contrasts with a profound inhibition of the primary immune response seen with the Ii-deficient mouse (46) , or the severely defective immune response of patients with bare lymphocyte syndrome (47) . Interestingly, B cells from Ii-deficient mice show a developmental arrest and do not generate a normal IgM response to a T cell-independent antigen (48) . This contrasts with results found in this study and from those observed with class II-deficient mice (39) , again suggesting that phenotypic differences exist between cathepsin S-deficient and Ii-deficient animals.
A possible clue to the basis of the partial effects seen with inhibition of cathepsin S is our observation that overall surface MHC class II levels, as judged by flow cytometry, and levels of surface class II-peptide complexes, as determined by surface biotinylation experiments, do not change after administration of LHVS for 2 wk (data not shown). This suggests that the kinetics of class II-peptide binding may be more profoundly affected than the final ability of class II molecules to associate with antigenic peptides. This is not totally unexpected because Figure 7 . In vivo administration of LHVS blocks perivascular inflammatory cell infiltration in OVA-induced pulmonary hypersensitivity. (A) Histological examination of murine lung sections from mice which were not sensitized to intraperitoneal OVA, but were exposed to nebulized OVA as a negative control. (B) Lung sections from mice sensitized and exposed to OVA demonstrating a prominent perivascular inflammatory cell infiltration. This is consistent with previous reports showing a prominent perivascular, eosinophilic infiltration in the lungs of mice using this model of pulmonary hypersensitivity (40, 41) . (C) Lung sections from mice sensitized and exposed to OVA as in B after treatment with LHVS (protocol as in Fig. 4 A) . Selective inhibition of LHVS profoundly blocked the perivascular inflammatory response. maturation of MHC class II molecules and generation of class II-peptide complexes require an intricate interplay of several proteolytic events. Class II-Ii complexes must be rendered competent for binding peptide by efficient degradation of intact Ii, antigenic peptides must be generated at sufficiently high concentrations to promote class II-peptide association, and degradation of antigenic peptides must not occur before the peptide can find refuge in the class II binding pocket. Thus, kinetic alteration of one or more of these determinants may result in a profound alteration in the immune response with a much less pronounced alteration of steady-state class II and class II-peptide levels. In support of this hypothesis, experimental evidence suggests that HLA-DM can interact, albeit less efficiently, with larger class II-Ii species compared with class II-CLIP (49) . Furthermore, different antigenic epitopes may have different intrinsic affinities for class II molecules and may be able to differentially displace Ii fragments. Taken together, these data suggest that inhibition of cathepsin S may act to selectively modulate, rather than broadly suppress, immunity.
To further characterize the role of cathepsin S in immunity, we used a model of Th-2-driven allergic inflammatory responses in the lung to test the functional effects of selective cysteine protease inhibition on a hypersensitivity reaction. A priori, modulation of the immune response by inhibition of cathepsin S using this model is appealing because of the known dependence of Th-2 T cell subset maturation on antigen presentation. Previous studies in splenocytes from transgenic T cell receptor mice, which respond to OVA 323-339 bound to class II molecules, show that Th-2 CD4 ϩ T cell subset maturation is dependent upon antigen dose (50), the affinity of peptide for the class II molecule, and hence the conformation of the class II-peptide complex (51) , and the APC as well (52) . Selective inhibition of cathepsin S had a profound effect on the development of pulmonary hypersensitivity in this model. This was evidenced by an attenuation of serum IgE titers as well as a blockade of inflammatory cell infiltration into the lung. Also, the abrogation of the IgE response may have an additive effect on the inability of the inhibited mice to effectively present antigenic peptide by preventing antigen capture and uptake through the CD23 and Fc⑀RIII IgE cell surface receptors (53) .
Pulmonary hypersensitivity and inflammation with eosinophilic infiltration is a prominent feature of allergic airway diseases, including asthma (54) . Activated eosinophils release several inflammatory mediators including cationic proteins, lipids, and oxygen radicals which participate in airway inflammation and injury (55) . Therapeutic strategies for modulating the immune response in asthma, and other autoimmune disorders, have centered on altering generation of the effector molecules which mediate the inflammatory reactions, e.g., corticosteroids, cyclosporin, and leukotriene inhibitors (56). Recently, attempts to inhibit more proximal events by blocking T cell costimulation have also been reported (42, 57) . Our experiments demonstrate that selective inhibition of cysteine proteases is an additional potential strategy for modulating the immune response in class II-restricted disease processes.
An important caveat to the in vivo studies is that we cannot be sure that only cathepsin S is inhibited. The second order rate constant for inhibition of cathepsin S is 6,000 times greater than that for cathepsin B, but only 60 and 30 times greater than that for cathepsins L and K, respectively (29) . Thus, in vivo, it is difficult to control the delivery of LHVS tightly enough to distinguish between these three cysteine endoproteases (cathepsins S, L, and K). Cathepsin K is not found in APCs, but cathepsin L is found in some murine B cells (Fig. 1 ) and dendritic cells (data not shown). Can cathepsin L compensate for the absence of cathepsin S in degrading Ii from ␣␤Ii complexes, rendering class II molecules competent for binding peptide? Both cathepsins S and L are potent endoproteases with overlapping, but not identical substrate profiles. Evidence in favor of a role for cathepsin L in Ii processing is found in mouse fibroblast 3T3 cells, in which inhibition of cathepsin L generates accumulation of Ii fragments similar to that seen with inhibition of cathepsin S in murine splenocytes and human B cells (24) . Evidence against a role for cathepsin L in Ii processing is provided by in vitro studies in our laboratory using purified human cysteine proteases and ␣␤Ii complexes, demonstrating that the concentration of cathepsin L required for generation of ␣␤-CLIP from ␣␤Ii complexes is Ͼ 10 times that of cathepsin S (data not shown). Furthermore, data presented in this manuscript with careful titration of LHVS in vitro with A20 cells (Figs. 1 and 2 ) demonstrate that cathepsin L cannot totally compensate for the absence of cathepsin S. This may be a consequence of kinetic differences in generation of ␣␤-CLIP, or may reflect differences in transport and compartmentalization of these two enzymes in A20 cells. Precise delineation of the exact roles of these two proteases in vivo may require genetic manipulation.
Recent experimental evidence has illustrated the importance of haplotype to class II-Ii processing. Although we have focused on cathepsin S, the realization that several class II-restricted diseases appear to be driven by only a few dominant antigenic epitopes, and by implication perhaps only a single protease, raises the possibility that selective inhibition of additional cysteine and lysosomal proteases may be immunomodulatory. For example, in vivo administration of an inhibitor of cathepsin B attenuates the antibody response to hepatitis B antigen in Balb/c mice, thought to occur by interruption of antigen processing (59) . Also, as stated above, cathepsin L has been linked to antigenic peptide degradation in murine fibroblast 3T3 cells (24) . Our experiments directly demonstrate a correlation between altered Ii processing, antigen presentation, and immunity. Thus, selective inhibition of cysteine proteases, cathepsin S in particular, may have important therapeutic potential in modulating class II-restricted immune processes.
